The role of a peripheral dopamine-antagonist (Motilium) in improving the tolerance to steroidal and non-steroidal anti-inflammatory agents.
Domperidone protective therapy has been applied in 50 patients suffering from locomotor disease, who responded with dyspeptic complaints to the steroidal and non-steroidal antiphlogistic therapies which meant a risk of the activation of an earlier gastro-intestinal disease. The basic therapy could be applied to 80% of patients due to the Motilium protection because of the favourable changes in gastro-intestinal symptoms. Since domperidone is well tolerated by the patients and it does not yield higher risks, it's use is highly recommended as a protective therapy as well.